Navigation Links
Drop Patent Petition, Activists Ask Novartis

Seeking to keep the price of a cancer drug affordable for masses, activists from several countries Monday gathered here and asked Swiss pharmaceutical major Novartis// to withdraw its case against the Indian government that has not granted patent to its anti-cancer medicine.

"India produces affordable medicines that help millions of people both here and in many other developing countries. A patent grant to Novartis on Gleevec will certainly make cancer medicine unaffordable for the poor," said Amit Sengupta, joint convenor of the PEOPLE'S Health Movement.

"While a generic drug for cancer costs Rs.8,000 for one month of treatment, Gleevec costs Rs.120,000. If Novartis gets the patent, then generic drugs will not be available in market," Sengupta told reporters.

In May 2006, Novartis had filed two cases against the government of India and the Cancer Patients Aid Association (CPAA) challenging the rejection of its patent application under the Indian Patent Law.

The company's application for a patent on Gleevec was opposed by the CPAA and subsequently rejected by the Chennai patent office in January 2006.

The application was rejected as it claimed Gleevec to be only a new form of an old drug and not an invention.

Unni Karunakara, medical director of the Medicins Sans Frontieres, a Netherlands-headquartered organisation, said that India is the main supplier of essential medicines for developing countries. Sixty-seven percent of the medicines produced in India are exported to developing countries, he said.

"A patent grant to Novartis will not only affect people in India but also millions of people in developing countries. It will set a wrong precedent for frivolous applicants to get patent by just tinkering molecules. Innovations of drugs will become difficult," Karunakara said.

"General public cannot afford the second line drugs as their cost will increase between seven to 30 times, " he added.

Michel Lotrowski, a Brazilian activist, said Novartis was embarking on sheer profiteering without even thinking of public health conditions.

K.M. Gopakumar, a member of the Centre for Trade and Development, said Novartis had challenged Section 3-D of the Indian Patent Act that dismisses frivolous patent applications as incongruous.

"Does the multinational want to say that the Indian government should frame law keeping in mind Novartis' profit motive? Can't we stop frivolous patent applications from seeing light?" Gopakumar asked.

Source-IANS
'"/>




Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: ... networking and recognition opportunities as well as advocacy for the state and region‘s ... on February 23. The Council's Innovation Forecast event highlights innovation throughout the ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: